Our mission is to improve the quality of life for all patients and their caregivers suffering
from Alzheimer's disease and related dementias.
Chase Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on the development of improved treatments for neurodegenerative disorders, including Alzheimer’s disease. The company’s development programs have the potential to profoundly improve the symptomatic treatment of Alzheimer's disease.
Chase is led by Chief Executive Officer Douglas S. Ingram, former President of Allergan, and was founded by Thomas N. Chase, MD, and Kathleen Clarence-Smith, MD, PhD, thought-leading neurologists who have dedicated their careers to improving the lives of patients with neurological disease.